← FDA DRUG APPROVALS

FDA ANDA · ANDA076310

CABERGOLINE

Sponsor: STRIDES PHARMA INTL

APPLICATION
ANDA076310
TYPE
ANDA
ORIGINAL APPROVAL
2005-12-29
LATEST ACTION
2026-03-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CABERGOLINEPrescription
CABERGOLINE 0.5MG · TABLET · ORAL

Approval history

2026-03-18Labeling · Supplement 18 · standardAP
2019-12-13Labeling · Supplement 11 · standardAP
2011-10-26Labeling · Supplement 5AP
2008-06-04Labeling · Supplement 2AP
2007-01-25Labeling · Supplement 1AP
2005-12-29OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →